EUVIMEDEUVIMED entdecken
Crossref

L26/P-384 One Technology, Two Models: Expanded Carrier Screening in Gamete Donation in the UK and Spain

C. Herbrand, M. Turrini

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. Herbrand und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question How is ECS implemented in gamete donation in the UK and Spain, and what factors shape these different approaches? Summary answer ECS follows two distinct models: a reactive, donor-status–driven matching approach in the UK and a proactive, algorithmic matching system embedded in Spain’s private reproductive market. What is known already ECS is increasingly offered in reproductive medicine to identify the risk that prospective biological parents may pass on pathogenic variants to their children (Capalbo et al. 2024; Delatycki et al, 2019). In Spain and the United Kingdom, ECS has first emerged and remains primarily embedded within the context of third-party gamete donation (Turrini et al. 2025, Herbrand et al. 2025). Despite the substantial use of gamete donation in both countries, little is known about how ECS is implemented in practice or how its implementation differs between the two settings. Study design, size, duration This study compares the implementation of ECS in gamete donation in Spain and the UK, two contrasting cases that illuminate the localisation of ECS. It applies an STS-informed comparative framework to examine the regulation and practice of ECS in medically assisted reproduction (Parthasarathy, 2007). The analysis draws on qualitative datasets collected in the UK (2023–2025) and Spain (2022–2024), comprising policy and clinical document analysis and semi-structured interviews with expert stakeholders. Participants/materials, setting, methods Across both projects, expert interviews (Bogner et al., 2009) were conducted with 49 key professional, policy, and commercial stakeholders (37 in the UK and 12 in Spain), alongside systematic mapping and analysis of relevant policy and clinical documents on ECS in each country. The combined datasets were recoded and comparatively analysed using thematic analysis (Braun & Clarke, 2006) to examine differences in regulatory drivers, testing approaches, information disclosure practices, and donor–recipient matching infrastructures. Main results and the role of chance Results show that ECS in gamete donation has developed along two sharply different socio-technical pathways. In the UK, ECS emerged reactively through the importation of donor gametes from international sperm banks already including carrier data. Clinics typically apply a targeted “match test” model: recipients are tested only for variants identified in selected donors. Implementation is heterogeneous, not mandatory, and shaped by regulatory caution, cost control, and concerns about legal liability and donor shortages. Information on donor carrier status is relatively transparent to recipients. In Spain, ECS developed proactively through internal innovation within a highly marketized assisted reproduction sector. It is widely integrated into donor selection through algorithmic genetic matching across large panels. Professional self-regulation and permissive legal frameworks support routine or near-routine ECS use in gamete donation. Donor anonymity is preserved while compatibility is computed through clinic-controlled platforms, producing a high-throughput matching model. Information to recipients is more limited, and matching operates as a technical “black box.” Differences are not attributable to chance but to structural factors: regulatory frameworks and cultures, reproductive market organization, and, in particular, donor supply systems. Limitations, reasons for caution The study is qualitative and institutionally focused, not statistically representative. It relies primarily on expert and documentary sources rather than patient interviews. National models are internally heterogeneous, and practices evolve rapidly. Findings should therefore be interpreted as analytically explanatory rather than quantitatively generalizable. Wider implications of the findings The comparison shows that genomic screening technologies, although being global technologies, do not travel as fixed tools but are reassembled within national reproductive infrastructures. Policy debates on ECS should address not only accuracy and ethics but also governance models, information asymmetries, and market effects in reproductive care. Trial registration number No

Zitieren

APA

Herbrand, C., & Turrini, M. (2026). L26/P-384 One Technology, Two Models: Expanded Carrier Screening in Gamete Donation in the UK and Spain. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.718

Vancouver

Herbrand C, Turrini M. L26/P-384 One Technology, Two Models: Expanded Carrier Screening in Gamete Donation in the UK and Spain. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.718

BibTeX
@article{Herbrand2026,
  author = {Herbrand, C. and Turrini, M.},
  title = {L26/P-384 One Technology, Two Models: Expanded Carrier Screening in Gamete Donation in the UK and Spain},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.718}
}
Kostenlos starten →